Page 717 - Hematology_ Basic Principles and Practice ( PDFDrive )

607.e2 Part VII Hematologic Malignancies

50. Zimmerman SA, Schultz WH, Burgett S, et al: Hydroxyurea therapy 74. Vichinsky EP, Haberkern CM, Neumayr L, et al: A comparison of
lowers transcranial Doppler flow velocities in children with sickle cell conservative and aggressive transfusion regimens in the perioperative
anemia. Blood 110:1043, 2007. management of sickle cell disease. The Preoperative Transfusion in
51. Kratovil T, Bulas D, Driscoll MC, et al: Hydroxyurea therapy lowers Sickle Cell Disease Study Group. N Engl J Med 333:206, 1995.
TCD velocities in children with sickle cell disease. Pediatr Blood Cancer 75. Howard J, Malfroy M, Llewelyn C, et al: The Transfusion Alternatives
47:894, 2006. Preoperatively in Sickle Cell Disease (TAPS) study: a randomised,
52. Gulbis B, Haberman D, Dufour D, et al: Hydroxyurea for sickle cell controlled, multicentre clinical trial. Lancet 381(9870):930–938,
disease in children and for prevention of cerebrovascular events: the 2013.
Belgian experience. Blood 105:2685, 2005. 76. Rosse WF, Gallagher D, Kinney TR, et al: Transfusion and alloim-
53. Ware RE, Zimmerman SA, Sylvestre PB, et al: Prevention of second- munization in sickle cell disease. The Cooperative Study of Sickle Cell
ary stroke and resolution of transfusional iron overload in children Disease. Blood 76:1431, 1990.
with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 77. Vichinsky EP, Earles A, Johnson RA, et al: Alloimmunization in sickle
145:346, 2004. cell anemia and transfusion of racially unmatched blood. N Engl J Med
54. Tavakkoli F, Nahavandi M, Wyche MQ, et al: Effects of hydroxyurea 322:1617, 1990.
treatment on cerebral oxygenation in adult patients with sickle cell 78. Vichinsky EP, Luban NL, Wright E, et al: Prospective RBC phenotype
disease: an open-label pilot study. Clin Ther 27:1083, 2005. matching in a stroke-prevention trial in sickle cell anemia: a multicenter
55. Najean Y, Rain JD, Dresch C, et al: Risk of leukaemia, carcinoma, transfusion trial. Transfusion 41:1086, 2001.
and myelofibrosis in 32P- or chemotherapy-treated patients with 79. Loos JA, Wautier JL: Leukocyte depletion: a biotechnical transfusion
polycythaemia vera: a prospective analysis of 682 cases. The “French story. Transfus Clin Biol 5:64, 1998.
Cooperative Group for the Study of Polycythaemias. Leuk Lymphoma 80. Bernaudin F, Souillet G, Vannier JP, et al: Bone marrow transplantation
22:111, 1996. (BMT) in 14 children with severe sickle cell disease (SCD): the French
56. Weinfeld A, Swolin B, Westin J: Acute leukaemia after hydroxyurea experience. GEGMO. Bone Marrow Transplant 12:118, 1993.
therapy in polycythaemia vera and allied disorders: prospective study 81. Locatelli F, Rocha V, Reed W, et al: Related umbilical cord blood
of efficacy and leukaemogenicity with therapeutic implications. Eur J transplantation in patients with thalassemia and sickle cell disease. Blood
Haematol 52:134, 1994. 101:2137, 2003.
57. Fruchtman SM, Mack K, Kaplan ME, et al: From efficacy to safety: a 82. Claster S, Vichinsky EP: Managing sickle cell disease. BMJ 327:1151,
Polycythemia Vera Study Group report on hydroxyurea in patients with 2003.
polycythemia vera. Semin Hematol 34:17, 1997. 83. Hsieh MM, Fitzhugh CD, Tisdale JF: Allogeneic hematopoietic
58. Triadou P, Maier-Redelsperger M, Krishnamoorty R, et al: Fetal hae- stem cell transplantation for sickle cell disease: the time is now. Blood
moglobin variations following hydroxyurea treatment in patients with 118:1197, 2011.
cyanotic congenital heart disease. Nouv Rev Fr Hematol 36:367, 1994. 84. Charache S, Dover GJ, Moore RD, et al: Hydroxyurea: effects on
59. Jonsson U, Roath OS, Kirkpatrick CI: Nutritional megaloblastic hemoglobin F production in patients with sickle cell anemia. Blood
anemia associated with sickle cell states. Blood 14:535, 1959. 79:2555, 1992.
60. Lopez R, Shimizu N, Cooperman JM: Recurrent folic acid deficiency 85. Markham MJ, Lottenberg R, Zumberg M: Role of phlebotomy in the
in sickle cell disease. Am J Dis Child 125:544, 1973. management of hemoglobin SC disease: case report and review of the
61. van der Dijs FP, Schnog JJ, Brouwer DA, et al: Elevated homocysteine literature. Am J Hematol 73:121, 2003.
levels indicate suboptimal folate status in pediatric sickle cell patients. 86. Ware RE, Zimmerman SA, Sylvestre PB, et al: Prevention of second-
Am J Hematol 59:192, 1998. ary stroke and resolution of transfusional iron overload in children
62. Pearson HA, Cobb WT: Folic acid studies in sickle-cell anemia. J Lab with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr
Clin Med 64:913, 1964. 145:346, 2004.
63. Dhar M, Bellevue R, Carmel R: Pernicious anemia with neuropsychi- 87. Bouchair N, Manigne P, Kanfer A, et al: Prevention of sickle cell crises
atric dysfunction in a patient with sickle cell anemia treated with folate with multiple phlebotomies. Arch Pediatr 7:249, 2000.
supplementation. N Engl J Med 348:2204, 2003. 88. Steinberg MH, Barton F, Castro O, et al: Effect of hydroxyurea on
64. Amer J, Ghoti H, Rachmilewitz E, et al: Red blood cells, platelets mortality and morbidity in adult sickle cell anemia: risks and benefits
and polymorphonuclear neutrophils of patients with sickle cell disease up to 9 years of treatment. JAMA 289:1645, 2003.
exhibit oxidative stress that can be ameliorated by antioxidants. Br J 89. Sherwood JB, Goldwasser E, Chilcote R, et al: Sickle cell anemia
Haematol 132:108, 2006. patients have low erythropoietin levels for their degree of anemia.
65. Lal A, Fung EB, Pakbaz Z, et al: Bone mineral density in children with Blood 67:46, 1986.
sickle cell anemia. Pediatr Blood Cancer 47:901, 2006. 90. Little JA, McGowan VR, Kato GJ, et al: Combination erythropoietin-
66. Buison AM, Kawchak DA, Schall J, et al: Low vitamin D status in hydroxyurea therapy in sickle cell disease: experience from the National
children with sickle cell disease. J Pediatr 145:622, 2004. Institutes of Health and a literature review. Haematologica 91:1076,
67. Schall JI, Zemel BS, Kawchak DA, et al: Vitamin A status, hospitaliza- 2006.
tions, and other outcomes in young children with sickle cell disease. 91. Breen CP, Macdougall IC: Improvement of erythropoietin-resistant
J Pediatr 145:99, 2004. anaemia after renal transplantation in patients with homozygous sickle-
68. Zemel BS, Kawchak DA, Fung EB, et al: Effect of zinc supplementa- cell disease. Nephrol Dial Transplant 13:2949, 1998.
tion on growth and body composition in children with sickle cell 92. Niederau C, Fischer R, Purschel A, et al: Long-term survival in patients
disease. Am J Clin Nutr 75:300, 2002. with hereditary hemochromatosis. Gastroenterology 110:1107, 1996.
69. Nolan VG, Nottage KA, Cole EW, et al: Prevalence of vitamin D 93. Brittenham GM, Cohen AR, McLaren CE, et al: Hepatic iron stores
deficiency in sickle cell disease: a systematic review. PLoS ONE and plasma ferritin concentration in patients with sickle cell anemia
10(3):e0119908, 2015. and thalassemia major. Am J Hematol 42:81, 1993.
70. Vichinsky E, Kleman K, Embury S, et al: The diagnosis of iron defi- 94. Porter JB, Huehns ER: Transfusion and exchange transfusion in sickle
ciency anemia in sickle cell disease. Blood 58:963, 1981. cell anaemias, with particular reference to iron metabolism. Acta
71. Alexy T, Pais E, Armstrong JK, et al: Rheologic behavior of sickle Haematol 78:198, 1987.
and normal red blood cell mixtures in sickle plasma: implications for 95. Karam LB, Disco D, Jackson SM, et al: Liver biopsy results in patients
transfusion therapy. Transfusion 46:912, 2006. with sickle cell disease on chronic transfusions: poor correlation with
72. Lottenberg R, Hassell KL: An evidence-based approach to the treatment ferritin levels. Pediatr Blood Cancer 50:62, 2008.
of adults with sickle cell disease. Hematology Am Soc Hematol Educ 96. Pakbaz Z, Fischer R, Fung E, et al: Serum ferritin underestimates liver
Program 58–65, 2005. iron concentration in transfusion independent thalassemia patients as
73. Charache S: Treatment of sickle cell anemia. Annu Rev Med 32:195, compared to regularly transfused thalassemia and sickle cell patients.
1981. Pediatr Blood Cancer 49:329, 2007.